Sub-analysis of cyp-guides data: Assessing the prevalence and impact of drug-gene interactions in an ethnically diverse cohort of depressed individuals
Abstract
Minority groups are underrepresented in pharmacogenomics (PGx)
research. Recent sub-analysis of CYP-GUIDES showed reduced length of stay (LOS)
in depressed patients with CYP2D6 sub-functional status. Our primary objective was to
determine whether PGx guided (G) versus standard treatment (S) influenced LOS among
different race/ethnic groups. Secondary objectives included prevalence of drug-gene
interactions (DGIs) and readmission rates (RAR). Retrospective sub-analysis of CYP-GUIDES data comprising CYP2D6
phenotypes was reclassified using standardized CYP2D6 genotype to phenotype
recommendations from the Clinical Pharmacogenetics Implementation Consortium
(CPIC) and Dutch Pharmacogenetics Working Group (DPWG).